Publication
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (9)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 9
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugCeritinibcivic_curation1.00
- drugCrizotinibcivic_curation1.00
- drugLorlatinibcivic_curation1.00
- drugLuminespibcivic_curation1.00
- geneALKcivic_curation1.00
- variantALK C1156Ycivic_curation1.00
- variantALK Fusioncivic_curation1.00
- variantALK L1198Fcivic_curation1.00
Curated evidence
Evidence citing this paper (10)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26698910
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ALK L1198F2 | ||||||||
| (predisposing) | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predisposing | C | Supports Predisposition | 3 | rejected | EID2942In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain. This mutation is predicted t… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC | civic |
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID4782In a metastatic EML4-ALK rearranged non-small cell lung carcinoma patient harboring ALK C1156Y (a known crizotinib resistance mutation) and ALK L1198F co-mutations, ALK L1198F was associated with rese… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC | civic |
| ALK C1156Y + ALK Fusion4 | ||||||||
| Ceritinib + Crizotinib + LuminespibSequential | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | 3 | accepted | EID841In this case report, a patient with metastatic, ALK-rearranged NSCLC with C1156Y mutation had tumor progression under sequential treatment with first crizotinib, then ceritinib and finally AUY922. Sub… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC | civic |
| Lorlatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID842Case report of a patient with metastatic ALK-rearranged NSCLC after progression under sequential crizotinib, ceritinib, HSP90 inhibitor AUY922 and chemotherapy followed by crizotinib again. Third gene… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC | civic |
| Crizotinib | Malignant NeoplasmALIAS | Predictive | D | Supports Resistance | 3 | submitted | EID7613Cells expressing EML4-ALK with the resistance mutation C1156Y were resistant to the ALK inhibitor crizotinib in vitro. In cell survival assays Ba/F3 cells with C1156Y treated with crizotinib had an IC… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC | civic |
| Alectinib + Brigatinib + Ceritinib + LorlatinibSubstitutes | Malignant NeoplasmALIAS | Predictive | D | Does Not Support Resistance | 4 | submitted | EID7609In vitro experiments showed that cells expressing EML4-ALK with the resistance mutation C1156Y were sensitive to second and third generation ALK inhibitors. In cell survival assays Ba/F3 cells with C1… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC | civic |
| ALK C1156Y + ALK L1198F + ALK Fusion3 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | 4 | accepted | EID844Case report of a patient with metastatic ALK-rearranged NSCLC. After developing resistance to first and second line ALK inhibitors mediated by a C1156Y mutation, the patient had a partial response wit… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC | civic |
| Lorlatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | C | Supports Resistance | 4 | accepted | EID843Case report of a patient with metastatic ALK-rearranged NSCLC. After developing resistance to first and second line ALK inhibitors mediated by a C1156Y mutation, the patient had a partial response wit… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC | civic |
| Crizotinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID7605The EML4-ALK fusion compound resistance mutation C1156Y-L1198F was shown to re-sensitize cells to crizotinib in vitro. In cell survival assays Ba/F3 cells expressing C1156Y-L1198F mutated EML4-ALK wer… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC | civic |
| ALK L1198F + ALK Fusion1 | ||||||||
| Crizotinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID7603The EML4-ALK fusion resistance mutation L1198F was shown to increase sensitivity of cells to crizotinib in vitro. In cell survival assays Ba/F3 cells expressing L1198F mutated EML4-ALK had even greate… (full text at CIViC) PMID 26698910 · Shaw et al., 2016 · Open in CIViC | civic |